Γ

SynBioBeta Speaker

Matt Anderson-Baron

Future Fields

CEO

Dr. Matt Anderson-Baron is the cofounder and CEO of Future Fields, an Edmonton-based biomanufacturing company that is redefining the production of recombinant proteins. Matt is the inventor of Future Fields pioneering technology, the EntoEngine™, the world’s first synthetic biology platform to utilize the common fruit fly (Drosophila melanogaster) as a sustainable, scalable alternative to traditional bioreactors.Driven by the mission to "make the unmakeable," Matt has been instrumental in transitioning Future Fields from a bold startup concept into a global biomanufacturing partner. The company now works with industry leaders across life sciences, agrisciences, and drug discovery by manufacturing proteins at scale with a fraction of the environmental footprint and cost associated with conventional methods.Matt is A PhD-trained cell biologist turned entrepreneur, and combines a deep scientific rigor with a passion for disruptive technology. Formerly a touring punk-rock musician before returning to academia, he leverages his unique background to foster a culture of curiosity with candor and innovation.Future Fields is committed to the sustainable biotech, as a Green-certified lab, and as members of 1% for the Planet and the UN Global Compact.

Sessions Featuring

Matt

This Year

Lightning Talk

11:18 AM

-

11:22 AM

Biomanufacturing

Thinking Outside the Tank: Biomanufacturing with Transgenic Drosophila

We have entered a golden age of biology, where AI tools can design novel molecules in minutes, functional tissues can be grown from stem cells, and human life can be extended. However, all of these innovations require scaling biomanufacturing and a massive gap remains. Traditional biomanufacturing platforms like CHO and E. coli are hindered by immense CAPEX requirements, slow infrastructure scaling, and biological bottlenecks - where creating a stable cell line alone can take upwards of 24 months. In this lightning talk, Future Fields introduces the EntoEngine™, a revolutionary biomanufacturing platform that replaces stainless steel tanks with the world’s most sophisticated multicellular bioreactor: Drosophila melanogaster. By moving beyond the tank, we eliminate the traditional trade-offs between speed, cost, quality, and protein complexity. We will showcase how the EntoEngine enables the predictable manufacturing of challenging proteins at a fraction of the time and cost of legacy systems. Discover how a decentralized, biology-first approach to manufacturing is essential to empowering the next generation of synthetic biology and reaching our goal of impacting one billion lives.

Lightning Talk

11:18 AM

-

11:22 AM

Biomanufacturing

Thinking Outside the Tank: Biomanufacturing with Transgenic Drosophila

We have entered a golden age of biology, where AI tools can design novel molecules in minutes, functional tissues can be grown from stem cells, and human life can be extended. However, all of these innovations require scaling biomanufacturing and a massive gap remains. Traditional biomanufacturing platforms like CHO and E. coli are hindered by immense CAPEX requirements, slow infrastructure scaling, and biological bottlenecks - where creating a stable cell line alone can take upwards of 24 months. In this lightning talk, Future Fields introduces the EntoEngine™, a revolutionary biomanufacturing platform that replaces stainless steel tanks with the world’s most sophisticated multicellular bioreactor: Drosophila melanogaster. By moving beyond the tank, we eliminate the traditional trade-offs between speed, cost, quality, and protein complexity. We will showcase how the EntoEngine enables the predictable manufacturing of challenging proteins at a fraction of the time and cost of legacy systems. Discover how a decentralized, biology-first approach to manufacturing is essential to empowering the next generation of synthetic biology and reaching our goal of impacting one billion lives.

TBD

Session lineup still growing

Featuring

Speaker Coming Soon

Fireside Chat

12:00 AM

-

8:30 AM

Human Health

From Cells to Patients: Solving the Scale Mismatch in Virtual Biology

Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?

Featuring

Speaker Coming Soon

Previous Speakers Include